Skip to main content

Table 2 Efficacy of traditional NSAIDs or iCOX2 vs. placebo in patients with axial spondyloarthritis: meta-analyses of randomized clinical trials

From: Brazilian recommendations for the use of nonsteroidal anti-inflammatory drugs in patients with axial spondyloarthritis

 

TRADITIONAL NSAIDs

n=1289

iCOX2

n=669

PAIN VAS (95% CI)

−16.75 (−20.28 to −13.07)

−21.68 (−35.94 to −7.42)

PGA

−17.75 (−24.39 to −11.10)

−20.82 (− 39.88 to −11.75)

ASAS20

60% vs. 23% (PbO)

RR=2.49 (1.94 to 3.19)

57% vs. 20% (PbO)

RR=2.51 (1.66 to 3.79)

BASFI

−9 (− 13 to −5)

−13.4 (− 17.3 to −5)

MS - SMD

−0.4 (−0.58 to −0.22)

NA

CRP mg/L

−3.37 (−6.11 to − 0.62)

NA

PAIN50%

48% vs 21%

2.25 (1.75 to 2.89)

NA

  1. NSAIDs nonsteroidal anti-inflammatory drugs, iCOX2 COX-2-selective inhibitors, PAIN VAS pain by visual analog scale 0–100 mm, PGA Patient Global Assessment 0–100 mm, BASFI Bath Ankylosing Spondylitis Function Index 0–100 mm, MS-SMD standardized mean difference in the duration of morning stiffness, CRP C-reactive protein, PAIN50% ≥ 50% improvement in pain, RR relative risk, PbO placebo, N/A meta-analysis not feasible
Back to article page

Advances in Rheumatology

ISSN: 2523-3106